What is Lactiga?
Lactiga is an award-winning, venture-backed biotechnology company dedicated to advancing immunoscience through the development of innovative mucosal antibody therapies. The company is at the forefront of utilizing secretory IgA antibodies, derived from human milk, to bolster mucosal immunity. This groundbreaking strategy aims to revolutionize treatment paradigms for chronic respiratory disorders and immune deficiencies by shifting therapeutic antibody delivery from systemic to mucosal routes, thereby targeting pathogens at their point of entry. Lactiga's core mission is to enhance the quality of life for vulnerable populations by creating more effective preventative and therapeutic solutions.
How much funding has Lactiga raised?
Lactiga has raised a total of $1.6M across 1 funding round:
Angel/Seed
$1.6M
Angel/Seed (2022): $1.6M with participation from 1517 Fund I
Key Investors in Lactiga
1517 Fund I
1517 Fund I is a venture capital and private equity firm that specializes in pre-seed and seed investments, indicating a focus on early-stage innovation and high-growth potential companies.
What's next for Lactiga?
With its recent major strategic investment, Lactiga is poised for significant expansion and acceleration of its research and development pipeline. The substantial capital infusion, part of its $1.6M total funding, will likely fuel the progression of its lead therapeutic candidates through clinical trials and support the scaling of its manufacturing capabilities. This enterprise-level backing suggests Lactiga is moving towards later-stage development and potential commercialization, aiming to establish a new standard in mucosal immunology treatments and address unmet medical needs in infectious diseases and autoimmune conditions.
See full Lactiga company page
